Professor, Oncologic Sciences, USF-Morsani
Oncology
Dr. Claudio Anasetti, MD
|
|
Give Review
Claudio Anasetti practices Oncology. He received 1 awards: "Super Doctor". Claudio Anasetti is a published doctor as well. He has 45 publications published. The latest was: Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Bone Marrow: A Prespecified Analysis from the Phase III BMT CTN Protocol 0201. Claudio Anasetti accepts Medicare payments and is listed with Medicare.gov.
Publications
- Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.
- T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice.
- Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic Cell transplantation: a single institution experie...
- The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
- Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic Cell transplantation: a single-center experience and a review of the literature.
- Ofatumumab in combination with glucocorticoids for primary therapy of Chronic graft vs. host disease: Phase I trial results.
- CD4+ T cell STAT3 phosphorylation precedes Acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.
- Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non...
- T-bet Is Critical for the Development of Acute Graft-versus-Host Disease through Controlling T Cell Differentiation and Function.
- Allogeneic hematopoietic Cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome.
- Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014.
- Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy.
- Non-permissive -DPB1 mismatch among otherwise HLA-matched donor-recipient pairs results in increased overall mortality after myeloablative unrelated allogeneic hematop...
- Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201.
- Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic Cell transplanta...
- STAT5 polarization promotes iTregs and suppresses human T-Cell alloresponses while preserving CTL capacity.
- Pre-transplant 5-azacitidine in high-risk Myelodysplastic syndrome.
- Health-related Quality of Life of Bone Marrow versus Peripheral Blood Stem Cell Donors: A Prespecified Subgroup Analysis from a Phase III RCT-BMTCTN Protocol 0201.
- Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord Blood transplantation for hematologic malignancy.
- Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic Cell transplantation for adults with ALL in first remission.
- Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
- Human regulatory T Cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease.
- Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe Acute GVHD and mortality.
- C-Rel is an essential transcription factor for the development of Acute graft-versus-host disease in mice.
- Allogeneic hematopoietic Cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
- Multiple mismatches at the low expression HLA loci DP, DQ, DRB3/4/5 associate with adverse outcomes in hematopoietic stem Cell transplantation.
- Phase II study of CD4+guided pentostatin lymphodepletion and pharmacokinetically-targeted busulfan as conditioning for hematopoietic Cell allografting.
- Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct Mechanisms.
- Hematopoietic Cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative.
- Practice variation in physician referral for allogeneic hematopoietic Cell transplantation.
- Dynamic Change and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice.
- A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic Cell transplantation.
- Stemness of B-Cell Progenitors in Multiple Myeloma Bone Marrow.
- Peripheral-blood stem Cells versus bone marrow from unrelated donors.
- Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.
- LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice.
- Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: Clinical and economic outcomes.
- Antithymocyte globulin for Acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review.
- Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myel...
- The Ever Elusive Permissive Mismatch.
- Quality of life after allogeneic hematopoietic Cell transplantation.
- Risk factors for Acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
- Tolerance Associated Gene Expression following Allogeneic Hematopoietic Cell Transplantation.
- Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Bone Marrow: A Prespecified Analysis from the Phase III BMT CTN Protocol 0201.
Schools
University Of Perugia ItalySchool Of Medicine
St Mary Hospital
University Of Perugia ItalyInternal Medicine
Children39s Memorial Hospital Oklahoma CityImmunology
University Of Washington and Fred Hutchinson Cancer Research Center Seattle WaOncology
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
University of Washington -
University of Perugia Faculty of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1871522995 | |
| NPPES Provider LastName | ANASETTI | |
| NPPES Provider FirstName | CLAUDIO | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 446.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 4.93 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871522995 |
| Last Name Of The Provider | ANASETTI |
| First Name Of The Provider | CLAUDIO |
| View All |
Similar Doctors
|
Dr. Gregoire Bergier, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Loretta S. Loftus, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Hugo F. Fernandez, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Martine Extermann, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jingsong Zhang, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Julie A. Kish, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Ragini Kudchadkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramesh Shah, MD
This Doctor is OpenDoctor Recommended.
|